These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35032047)

  • 1. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Kim ES; Choi S; Choi SY; Park JH; Choe BH; Lee SY; Kim MJ; Choe YH; Kang B
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1008-1015. PubMed ID: 35032047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
    Colman RJ; Vuijk SA; Mathôt RAA; Van Limbergen J; Jongsma MME; Schreurs MWJ; Minar P; de Ridder L; D'Haens GRAM
    Inflamm Bowel Dis; 2024 Oct; 30(10):1678-1685. PubMed ID: 38167922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.
    Jeong TJ; Kim ES; Kwon Y; Kim S; Seo SW; Choe YH; Kim MJ
    Sci Rep; 2022 Jan; 12(1):507. PubMed ID: 35017546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Kang B; Kim TJ; Choi J; Baek SY; Ahn S; Choi R; Lee SY; Choe YH
    Aliment Pharmacol Ther; 2020 Aug; 52(3):459-470. PubMed ID: 32598049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
    Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].
    Qian G; Hongxia D; Jin LI
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):453-458. PubMed ID: 32895126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease.
    Melek J; Štanclová M; Dědek P; Malý J; Bayer M; Pozler O; Bureš J
    J Dig Dis; 2020 Dec; 21(12):705-710. PubMed ID: 32755026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early serum infliximab trough level and mucosal healing could be predictors for one-year outcome after initiating therapy in Crohn's disease.
    Tang J; Yang Q; Huang Z; Guo H; Chao K; Hu P; Gao X
    Scand J Gastroenterol; 2020 Sep; 55(9):1035-1040. PubMed ID: 32819192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn's disease.
    Choi SY; Kwon Y; Choi S; Lee SM; Choe BH; Kang B
    Front Immunol; 2023; 14():1192827. PubMed ID: 37426637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
    Jongsma MME; Aardoom MA; Cozijnsen MA; van Pieterson M; de Meij T; Groeneweg M; Norbruis OF; Wolters VM; van Wering HM; Hojsak I; Kolho KL; Hummel T; Stapelbroek J; van der Feen C; van Rheenen PF; van Wijk MP; Teklenburg-Roord STA; Schreurs MWJ; Rizopoulos D; Doukas M; Escher JC; Samsom JN; de Ridder L
    Gut; 2022 Jan; 71(1):34-42. PubMed ID: 33384335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to Infliximab in children with luminal Crohn's disease.
    Grover Z; Biron R; Carman N; Lewindon P
    J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
    Ohem J; Hradsky O; Zarubova K; Copova I; Bukovska P; Prusa R; Malickova K; Bronsky J
    Dig Dis; 2018; 36(1):40-48. PubMed ID: 28817809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
    Kang B; Choi SY; Choi YO; Kim MJ; Kim K; Lee JH; Choe YH
    J Crohns Colitis; 2018 May; 12(6):644-652. PubMed ID: 29474531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators.
    Kansen HM; van Rheenen PF; Houwen RHJ; Tjon A Ten W; Damen GM; Kindermann A; Escher JC; Wolters VM;
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):425-429. PubMed ID: 28945207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China.
    Zhang T; Wang Z; Fan R; Zhang M; Lin Y; Hong L; Zhou X; Hu S; Cheng M; Zhong J
    Biomed Res Int; 2016; 2016():8648307. PubMed ID: 27896276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.